Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
BERKELEY, Calif., Sept. 22, 2016 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on Thursday, September 29, 2016, at 8:00 am Eastern Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Alexandra Santos Sr. Director, Corporate Affairs 510 809 9231 Media Contact: Angela Bitting 925 202 6211 [email protected]
